Seminars in Oncology
Volume 37, Issue 1 , Pages 11-19 , February 2010

The Role of Anti–Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?

References 

  1. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis (The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients). Arthritis Rheum. 2004;50:1740–1751
  2. Weyad CM, Goronzy JJ, Kurtin PJ. Editorial—lymphoma in rheumatoid arthritis (An immune sysem set up for failure). Arthritis Rheum. 2006;54:685–689
  3. Van Vollenhoven RF. Benefits and risks of biological agents (Lymphoma). Clin Exp Rheumatol. 2004;22(suppl 35):S122–s125
  4. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2757–2764
  5. Fulchiero GJ, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56:S65–S67
  6. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–148
  7. Fulchiero GJ, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(Suppl):S65–S67
  8. Buchbinder R, Barber M, Huezenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59:794–799
  9. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2757–2764
  10. Chakravarty EF, Farmer ER. Risk of skin cancer in the drug treatment of rheumatoid arthritis. Expert Opin Drug Safety. 2008;7:539–546
  11. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20:334–339
  12. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (ATTRACT Study Group). Lancet. 1999;354:1932–1939
  13. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–1593
  14. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–1411
  15. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002;13:135–141
  16. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005;44:157–163
  17. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP. European Biologics Registers—methodology, selected results, and perspectives. Ann Rheum Dis. 2009;68:1240–1246
  18. Strangfeld A, Listing J, Herzer P, et al. RA patients with prior malignancy under treatment with biologics. [abstract] Ann Rheum Dis. 2008;67(Suppl II):
  19. Dixon WG, Watson KD, Lunt M, et al. The influence of anti-TNF therapy upon cancer incidence in patients with rheumatoid arthritis (RA) who have had prior malignancy: results from the BSRBR [abstract]. Arthritis Rheum. 2008;58(Suppl):S638–S639
  20. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886–2895
  21. Eggermont AM, ten Hagen TL. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep. 2003;5:79–80
  22. Agius E, Lacy KE, Vukmanovic-Stejic M, et al. Decreased TNF-α synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med. 2009;206:1929–1940
  23. Food and Drug Administration. Food and Drug Administration Amendments Act of 2007. Public Law 110-85. September 27, 2007;

PII: S0093-7754(10)00012-6

doi: 10.1053/j.seminoncol.2010.01.001

Seminars in Oncology
Volume 37, Issue 1 , Pages 11-19 , February 2010

Article Tools

* Image Usage & Resolution